BlackRock’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $485K | Sell |
407,622
-531,085
| -57% | -$632K | ﹤0.01% | 4380 |
|
|
2025
Q1 | $1.91M | Sell |
938,707
-6,789
| -0.7% | -$13.8K | ﹤0.01% | 3968 |
|
|
2024
Q4 | $5.69M | Buy |
945,496
+158,514
| +20% | +$954K | ﹤0.01% | 3622 |
|
|
2024
Q3 | $5.51M | Buy |
786,982
+19,962
| +3% | +$140K | ﹤0.01% | 3613 |
|
|
2024
Q2 | $4.45M | Buy |
767,020
+23,119
| +3% | +$134K | ﹤0.01% | 3677 |
|
|
2024
Q1 | $5.32M | Buy |
743,901
+178,069
| +31% | +$1.27M | ﹤0.01% | 3590 |
|
|
2023
Q4 | $2.78M | Buy |
565,832
+37,072
| +7% | +$182K | ﹤0.01% | 3837 |
|
|
2023
Q3 | $5.05M | Sell |
528,760
-4,595
| -0.9% | -$43.9K | ﹤0.01% | 3603 |
|
|
2023
Q2 | $6.91M | Buy |
533,355
+59,128
| +12% | +$766K | ﹤0.01% | 3509 |
|
|
2023
Q1 | $6.02M | Buy |
+474,227
| New | +$6.02M | ﹤0.01% | 3480 |
|